http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Kite to Acquire Tmunity Therapeutics to Pursue Next Generation CAR T-Cell Therapy Advancements in Cancer
-
Gilead (GILD) and Arcus (RCUS) Report Strong Interim Results of ARC-7 Study
-
Anti-TIGIT Domvanalimab-Containing Study Arms Improve Progression-Free Survival Compared to Anti-PD1 Alone in Phase 2 Non-Small Cell Lung Cancer Study
-
Anti-TIGIT Domvanalimab-Containing Study Arms Improve Progression-Free Survival Compared to Anti-PD1 Alone in Phase 2 Non-Small Cell Lung Cancer Study
-
Gilead Sciences Again Named to Dow Jones Sustainability World Index
-
New Analyses of Kite's Tecartus® CAR T-Cell Therapy Provide Additional Evidence Supporting Overall Survival and Durability of Response
-
Three-Year Follow-Up Analysis of Kite’s Yescarta® CAR T-cell Therapy (ZUMA-5 Trial) - 52% of Patients With Indolent Lymphomas Continued to Have Ongoing Responses at a Median Follow-Up of 40.5 Month
-
Body of Evidence Grows From ZUMA-7 Study Supporting Initial Treatment With Kite’s Yescarta® CAR T-cell Therapy for Patients With Relapsed or Refractory Large B-cell Lymphoma
-
Kite and Arcellx Announce Strategic Collaboration to Co-develop and Co-commercialize Late-stage Clinical CART-ddBCMA in Multiple Myeloma
-
Arcellx (ACLX) and Kite (GILD) Announce Strategic Collaboration to Co-Develop and Co-Commercialize Late-Stage Clinical CART-ddBCMA in Multiple Myeloma
-
Arcellx and Kite Announce Strategic Collaboration to Co-Develop and Co-Commercialize Late-Stage Clinical CART-ddBCMA in Multiple Myeloma
-
New Data for Trodelvy Demonstrate Clinical Efficacy Across Trop-2 Expression Levels in HR+/HER2- Metastatic Breast Cancer
-
Gilead Sciences (GILD) Announces EC Grants Expanded Marketing Authorization for Biktarvy for the Treatment of HIV in Pediatric Populations
-
European Commission Grants Expanded Marketing Authorization for Gilead’s Biktarvy® for the Treatment of HIV in Pediatric Populations
-
Gilead (GILD) and Arcus Biosciences (RCUS) Announce Positive Update on Joint TIGIT Program From Interim Analysis of ARC-7 Study in Non-small Cell Lung Cancer
-
Gilead and Arcus Biosciences Announce Positive Update on Joint TIGIT Program From Interim Analysis of ARC-7 Study in Non-Small Cell Lung Cancer
-
Gilead and Arcus Biosciences Announce Positive Update on Joint TIGIT Program From Interim Analysis of ARC-7 Study in Non-small Cell Lung Cancer
-
Gilead Sciences to Present at Upcoming Investor Conferences
-
Gilead, Kite in process of pausing Twitter advertising
-
Gilead and Kite Oncology Demonstrate Transformative Impact of Cell Therapy and Promise of Blood Cancer Portfolio at ASH 2022
-
Gilead Sciences (GILD) Announces Approves Vemlidy for Treatment of Chronic Hepatitis B Virus Infection in Pediatric Patients
-
U.S. Food and Drug Administration Approves Vemlidy® (tenofovir alafenamide) for Treatment of Chronic Hepatitis B Virus Infection in Pediatric Patients
-
Gilead to Present Data Across Viral Hepatitis and Liver Fibrosis at The Liver Meeting® 2022, Reinforcing Gilead as a Leader in Addressing Treatment Needs for People Living With Liver Disease
-
Gilead Sciences (GILD) Reports Real-World Evidence Reinforcing the Use of Biktarvy for the Treatment of HIV
-
Gilead Presents Real-World Evidence Reinforcing the Use of Biktarvy® for the Treatment of People Living With HIV With a Range of Comorbidities
-
Gilead Sciences (GILD) Kite and Refuge Biotechnologies Announce Exclusive License Agreement for Investigational Gene Expression Platform for Blood Cancers
-
Kite and Refuge Biotechnologies Announce Exclusive License Agreement for Investigational Gene Expression Platform for Blood Cancers
-
Gilead Sciences (GILD) Presents Real-World and Long-Term Data From HIV Research Programs at HIV Glasgow 2022
-
Gilead Presents Real-World and Long-Term Data From HIV Research Programs at HIV Glasgow 2022
-
Gilead(GILD) Announces Kite’s Yescarta First CAR T-cell Therapy to Receive European Marketing Authorization for Use in Second-Line Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma
-
Kite’s Yescarta First CAR T-cell Therapy to Receive European Marketing Authorization for Use in Second-Line Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma
-
Gilead Sciences (GILD) and MacroGenics (MGNX) Announce Oncology Collaboration to Develop Bispecific Antibodies
-
Gilead and MacroGenics Announce Oncology Collaboration to Develop Bispecific Antibodies
-
Gilead Sciences to Release Third Quarter 2022 Financial Results on Thursday, October 27, 2022
-
Gilead Sciences (GILD) Announces U.S. FDA Accepts for Priority Review sBLA for Trodelvy for Pre-Treated HR+/HER2- Metastatic Breast Cancer
-
U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Gilead’s Trodelvy® for Pre-Treated HR+/HER2- Metastatic Breast Cancer
-
Gilead Sciences' (GILD) Kite Receives U.S. FDA Approval of Viral Vector Manufacturing Facility in Southern California to Produce Commercial Product
-
Kite Receives U.S. FDA Approval of Viral Vector Manufacturing Facility in Southern California to Produce Commercial Product
-
Gilead Joins First-of-its-Kind Public-Private Initiative to Improve Management of Viral Hepatitis in Vietnam and the Philippines
-
Gilead Sciences (GILD) Completes Acquisition of MiroBio
-
Gilead Sciences Completes Acquisition of MiroBio
-
Gilead Sciences (GILD) Announces Kite's CAR T-cell Therapy Yescarta First in Europe to Receive Positive CHMP Opinion for Use in Second-line Diffuse Large B-cell Lymphoma and HGBL
-
Kite’s CAR T-cell Therapy Yescarta® First in Europe to Receive Positive CHMP Opinion for Use in Second-line Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma
-
Gilead Sciences (GILD) Reports Positive CHMP Opinion for Treatment of Pediatric Patients with Veklury
-
CHMP Adopts Positive Opinion to Extend Indication of Veklury® (Remdesivir) for the Treatment of Pediatric Patients with COVID-19
-
Gilead Sciences (GILD) Announces WHO's Expanded Recommendation for Veklury for Patients With Severe COVID-19
-
WHO Expands Recommendation for Veklury® (Remdesivir) to Patients With Severe Disease in Latest Update to COVID-19 Guideline
-
Gilead Foundation Awards $20 Million to Organizations Working to Advance Health Through Education Equity
-
Trodelvy® Significantly Improved Overall Survival in Pre-Treated HR+/HER2- Metastatic Breast Cancer Patients in TROPiCS-02 Study
-
Kite’s CAR T-cell Therapy Tecartus® Granted European Marketing Authorization for the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia (r/r ALL)
